APT Pharma Raises $22 Million

APT Pharmaceuticals Inc., a Burlingame, Calif.-based drug company whose pipeline includes a Phase III drug for the prevention of lung transplant rejection, has raised $22 million in Series A-2 funding. Versant Ventures and Great Point Partners were joined by return backers Vivo Ventures and Charter Life Sciences. Camille Samuels of Versant and David Kroin of Great Point with join the APT, which has now raised $30 million to date. www.aptbio.com